Merck in agreement with HAPPYneuron to offer first-of-its kind e-Health solution for people living with multiple sclerosis

MerckMerck, a leading science and technology company, announced today that the company has entered into an agreement with HAPPYneuron, a subsidiary of SBT Group of France, in which Merck will receive an exclusive license to the company's cognitive remediation training program for people living with multiple sclerosis (MS). This agreement complements Merck’s broad portfolio of patient support programs in MS and underscores the company's commitment to leveraging digital platforms and technologies to benefit patients in need. Financial terms of the deal were not disclosed.

HAPPYneuron's cognitive remediation program will be available for inclusion in Merck's MSdialog platform, when deemed beneficial for a patient by his/her healthcare provider. HAPPYneuron is designed to improve cognitive skills through brain training by repeated cognitive game training exercises. The in-licensing and integration of HAPPYneuron into the MSdialog platform will allow Merck to expand its first-of-its-kind eHealth solution for people living with MS.

"We have a long-standing commitment to delivering therapeutic and support solutions to people living with MS," said Rehan Verjee, Chief Marketing and Strategy Officer of Merck's biopharma business. "The platform will enhance the attractiveness of MSdialog to patients and HCPs by seeking to address these cognitive deficit symptoms and further fostering the monitoring of the cognitive state of patients."

The HAPPYneuron software-based cognitive training is backed by more than 10 years of clinical data and is designed to address cognitive function across various domains.

HAPPYneuron's suite of cognitive training games are designed to address the cognition challenges that people living with MS face, and the games automatically adjust skill to match the need of the individual - making the platform interesting for the patient and simple for healthcare professionals to use with their patients.

"We are very proud that Merck chose our program," said Franck Tarpin-Bernard, HAPPYneuron President. "This agreement is a strong acknowledgement of the hard work we have achieved these past years to build training programs adapted to the uniqueness of each medical condition. It reinforces our willingness to become a world leader of digital cognitive remediation."

MSdialog is a multi-tenant cloud-based software system for the management of MS that captures and presents patient outcome data to enable better decision-making by patients and providers. The software system provides patients with reminders to take their Rebif® (interferon beta-1a) medication, synchronizes with the new RebiSmart® auto-injector, monitors patient's adherence information to their treatment, and monitors clinical data. MSdialog also allows people with MS to engage in the management of their disease by asking them to complete periodic health report questionnaires based on short forms of published instruments and standard scales, such as the Multiple Sclerosis Quality of Life Inventory (MSQLI) and the Multiple Sclerosis International Quality of Life (MusiQoL) questionnaires.

MSdialog is currently available in 24 countries. MSdialog with HAPPYneuron will be made available to MS patients initially in a phased roll out beginning in Brazil, Argentina, Israel, Italy, France, and the Netherlands.

About HAPPYneuron
HAPPYneuron is the Smart Health division of SBT Group and a pioneer of brain training industry. Based in France and the United States, HAPPYneuron designs specific cognitive remediation solutions with a rich library of over 200 customizable activities, unique algorithms for analyzing performance, and coaching features.

Its main products target patients suffering from medical conditions that affect cognitive functions (stroke, Alzheimer's, schizophrenia, depression, multiple sclerosis, learning and attention disorders, etc.) and health professionals (speech therapists, neuropsychologists, occupational therapists, psychiatrists , etc.) looking for powerful rehabilitation tools. With its experimented scientific and technological knowledge, HAPPYneuron also adapts and integrates its programs inside third-party platforms (pharmaceutical industry, insurance companies, etc.).

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2015, Merck generated sales of € 12.85 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

Top 20 breaking World Pharma News of 2018

World Pharma News proudly presents the top 20 most popular breaking news from 2018. Have a wonderful 2019 New(s) Year filled with health, happiness, and spectacular succe...

FDA approves first treatment for rare blood diseas…

The U.S. Food and Drug Administration today approved Elzonris (tagraxofusp-erzs) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adu...

Bristol-Myers Squibb to acquire Celgene to create …

Bristol-Myers Squibb Company (NYSE:BMY) and Celgene Corporation (NASDAQ:CELG) today announced that they have entered into a definitive merger agreement under which Bristo...

Lynparza meets primary endpoint in Phase III SOLO-…

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) announced positive results from the randomised, open-label, contro...

Pediatric leukemia 'super drug' could be developed…

Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published ...

Researchers uncover new mechanism of gene regulati…

Genes contain all the information needed for the functioning of cells, tissues, and organs in our body. Gene expression, meaning when and how are the genes being read and...

AstraZeneca announces organisational changes

AstraZeneca is today announcing organisational changes to support continued scientific innovation and commercial success in the main therapy areas as the Company enters a...

Tumors backfire on chemotherapy

Some patients with breast cancer receive chemotherapy before the tumor is removed with surgery. This approach, called 'neoadjuvant' therapy, helps to reduce the size of t...

Sandoz and Pear Therapeutics announce US launch of…

Sandoz Inc., a Novartis division, and Pear Therapeutics, Inc., announced today the US commercial launch of reSET-O(TM) for patients with Opioid Use Disorder (OUD). reSET-...

Stopping cancer from recruiting immune system doub…

Cancerous tumors trick myeloid cells, an important part of the immune system, into perceiving them as a damaged part of the body; the tumors actually put myeloid cells to...

Boehringer Ingelheim initiates a collaborative par…

Science 37, an industry leader in virtual clinical trials, and Boehringer Ingelheim announced a technology enterprise collaboration agreement that will support Boehringer...

Pfizer initiates phase 2b/3 clinical trial for PF-…

Pfizer Inc. (NYSE: PFE) announced the initiation of a Phase 2b/3 clinical trial for its oral JAK3 inhibitor, PF-06651600, for the treatment of patients with moderate to s...